"Race researchers have developed an improved & novel formulation of Zantrene
that enables peripheral intravenous (IV) delivery, expanding potential market"
Certainly an IV administration is easier
As it is a "novel" formulation any one know if safety trials etc etc will be required before any clinical trials?
"Race has signed a contract with Societal (San Diego, California, USA) to produce the new
RC220 IV formulation to the FDA current Good Manufacturing Practice (cGMP) standard
that is required for use in clinical trials."
FDA approval also needed
Ann: Race Develops Improved IV Formulation of Zantrene, page-14
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
0.010(0.57%) |
Mkt cap ! $298.0M | |||
| Open | High | Low | Value | Volume |
| $1.73 | $1.83 | $1.73 | $272.0K | 152.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9998 | $1.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |